Product Information

CAS No.	300832-84-2
Product Name	Ciluprevir

Heavy Atom Count	55	Rotatable Bond Count	9
Atom Stereo Count	5	Bond Stereo Count	1
HBA	11	HBD	4
TPSA	181.310 Å²	Charge	0
Exact Mass	774.34108	Complexity	1944.97
pKa	4.610	XLogP	6.053

Studies related to this compound and its mechanism of action

Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.

Antimicrobial agents and chemotherapy • Vol. 52, Issue 5 • 2008

PMID: 18332167 PMC: PMC2346627 DOI: 10.1128/AAC.01208-07

Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.

Gastroenterology • Vol. 133, Issue 4 • 2007

PMID: 17919490 DOI: 10.1053/j.gastro.2007.07.007

Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.

Bioorganic & medicinal chemistry • Vol. 15, Issue 3 • 2007

PMID: 17113777 DOI: 10.1016/j.bmc.2006.11.003

Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.

Bioorganic & medicinal chemistry • Vol. 14, Issue 15 • 2006

PMID: 16675222 DOI: 10.1016/j.bmc.2006.04.008

Ciluprevir

CAS No.	300832-84-2
MDL No.	N/A
MF	C₄₀H₅₀N₆O₈S
MW	774.90
InChI Key	PJZPDFUUXKKDNB-KNINVFKUSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	300832-84-2
Product Name	Ciluprevir

Heavy Atom Count	55	Rotatable Bond Count	9
Atom Stereo Count	5	Bond Stereo Count	1
HBA	11	HBD	4
TPSA	181.310 Å²	Charge	0
Exact Mass	774.34108	Complexity	1944.97
pKa	4.610	XLogP	6.053

Ciluprevir

Pricing & Availability

Product Information

Properties

Ciluprevir

Pricing & Availability

Product Information

Properties

Documentation

Ciluprevir

Pricing & Availability

Product Information

Properties

Related Articles

Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.

Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.

Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.

Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.

Similar Products

Gs-9256

Ciluprevir

Pricing & Availability

Product Information

Properties

Related Articles

Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.

Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.

Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.

Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.

Similar Products

Gs-9256

Documentation